Vlad Coric (Photo Credit: Andrew Venditti)
Biohaven scores CGRP OK for acute migraine — can the commercial team catch up with Allergan on its debut?
Seven years after spinning out of Yale, Biohaven has entered the ranks of commercial-stage biotechs.
The FDA handed down an OK for its CGRP drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
